14 July 2014 : Original article
The Pharmacokinetics of Everolimus in De Novo Kidney Transplant Patients Receiving Tacrolimus: An Analysis from the Randomized ASSET Study
Lionel RostaingABE, Maarten H.L. ChristiaansABE, John M. KovarikCE, Julio PascualABEDOI: 10.12659/AOT.890673
Ann Transplant 2014; 19:337-345
Abstract
BACKGROUND: Pharmacokinetic data regarding a drug-drug interaction between everolimus and tacrolimus are sparse.
MATERIAL AND METHODS: In a pharmacokinetic substudy of the randomized ASSET trial, 46 de novo kidney transplant patients receiving very low (1.5–3 ng/mL) or low (4–7 ng/mL) tacrolimus exposure after month 3, both with everolimus and steroids, provided area under the curve (AUC) concentration profiles at day 5 and months 1, 3, and 12.
RESULTS: At month 12, mean values for tacrolimus trough concentration (C0), peak concentration (Cmax), and AUC0–12 in the very low tacrolimus group were approximately half that in the low tacrolimus group, but everolimus dose, C0, Cmax, and AUC0–12 were virtually identical in both groups. In a cross-study comparison with data at months 1 and 3 from the pharmacokinetic substudy of the A2307 trial, in which patients received cyclosporine, mean values for everolimus C0, Cmax and AUC0–12 were similar to those in the ASSET trial but the everolimus dose needed to achieve similar exposure was 1.5- to 2-fold higher with concomitant tacrolimus versus cyclosporine.
CONCLUSIONS: Everolimus exposure is unaffected when tacrolimus exposure is down-titrated within the trough concentration range of 1.5–7 ng/mL. Higher doses of everolimus are needed to achieve a given exposure when combined with tacrolimus versus cyclosporine.
Keywords: Kidney Transplantation, Pharmacokinetics, Tacrolimus
In Press
Original article
Outcomes of Combined Liver-Kidney Transplantation in Polycystic Liver and Kidney DiseaseAnn Transplant In Press; DOI: 10.12659/AOT.947639
Most Viewed Current Articles
03 Jan 2023 : Original article 6,893
Impact of Autologous Stem Cell Transplantation on Primary Central Nervous System Lymphoma in First-Line and...DOI :10.12659/AOT.938467
Ann Transplant 2023; 28:e938467
15 Aug 2023 : Review article 6,848
Free-Circulating Nucleic Acids as Biomarkers in Patients After Solid Organ TransplantationDOI :10.12659/AOT.939750
Ann Transplant 2023; 28:e939750
16 May 2023 : Original article 6,597
Breaking Antimicrobial Resistance: High-Dose Amoxicillin with Clavulanic Acid for Urinary Tract Infections ...DOI :10.12659/AOT.939258
Ann Transplant 2023; 28:e939258
28 May 2024 : Original article 5,949
Effect of Dexmedetomidine Combined with Remifentanil on Emergence Agitation During Awakening from Sevoflura...DOI :10.12659/AOT.943281
Ann Transplant 2024; 29:e943281